Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361423 | 0.73 | NPSR1 (0.47) | TSHRL3MBTL1 | |
| SCHEMBL5362970 | 0.71 | MEN1 (0.40) | TSHRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL5370826 | 0.70 | MEN1 (0.39) | TSHRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL5370815 | 0.69 | NTRK1 (0.39) | SMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL5717559 | 0.65 | MTNR1B (0.35) | MAPK1 | |
| SCHEMBL3214592 | 0.65 | KDM1A (0.36) | SMN1; SMN2 | |
| SCHEMBL24110592 | 0.65 | MTNR1A (0.37) | — | |
| SCHEMBL5369243 | 0.64 | CDK4 (0.36) | SMN1; SMN2 | |
| SCHEMBL11541996 | 0.63 | HTR2C (0.40) | TSHRMAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL24110207 | 0.62 | HTR2C (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235550-B2 | Polycyclic azaindole compounds | LES LABORATOIRES SERVIER (FR) | 2007-06-26 | — | — | US | disclosed |
| US-6667304-B2 | Affinity for melatonin receptors; sleep disorders; N-(2-(2-methoxy-6H-pyrido(2',3':4,5)pyrrolo(2,1-a)isoindol-11 -yl)ethyl)acetamide; N-(2-(3-methoxy-6,7,8,9-tetrahydropyrido (3,2-b)indolizin-5-yl) ethyl)acetamide | LES LABORATOIRES SERVIER (FR) | 2003-12-23 | — | — | US | disclosed |
| US-20030134847-A1 | New polycyclic azaindole compounds | GUILLAUMET GERALD (FR) | 2003-07-17 | — | — | US | disclosed |
| US-20030105087-A1 | For therapy of melatoninergic disorders | GUILLAUMET GERALD (FR) | 2003-06-05 | — | — | US | disclosed |
| EP-1092717-B1 | Polycyclic azaindole derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-01-08 | — | — | EP | disclosed |
| US-6495543-B1 | TREATING OR PREVENTING MELATONINERGIC DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-12-17 | — | — | US | disclosed |
| EP-1092717-A2 | Polycyclic azaindole derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134847-A1 | New polycyclic azaindole compounds | AZI2, DRD3, CCNI | TSHR 1941/4885MAPK1 1840/4885SMN1; SMN2 3576/4885 |
| US-20030105087-A1 | For therapy of melatoninergic disorders | MTNR1A, MTNR1B, TPH1 | TSHR 330/4885MAPK1 1782/4885SMN1; SMN2 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.